Public Profile

Orexo

Orexo AB, a leading pharmaceutical company headquartered in Sweden, focuses on developing innovative treatments for addiction and pain management. Founded in 1995, Orexo has established a strong presence in Europe and North America, with a commitment to addressing unmet medical needs through advanced drug delivery technologies. The company’s core products, including Zubsolv, a sublingual film for opioid dependence, exemplify its unique approach to patient care. Orexo's dedication to research and development has positioned it as a key player in the pharmaceutical industry, with notable achievements in improving treatment outcomes for patients struggling with addiction. With a robust pipeline and a focus on sustainable growth, Orexo continues to make significant strides in enhancing the quality of life for individuals facing complex health challenges.

DitchCarbon Score

How does Orexo's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

57

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Orexo's score of 57 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.

74%

Let us know if this data was useful to you

Orexo's reported carbon emissions

In 2024, Orexo reported total carbon emissions of approximately 1,537,000 kg CO2e. This figure includes Scope 1 emissions of about 312,000 kg CO2e, Scope 2 emissions of approximately 366,000 kg CO2e, and significant Scope 3 emissions amounting to about 859,000 kg CO2e. Comparatively, in 2023, Orexo's total emissions were about 2,006,000 kg CO2e, with Scope 1 emissions at approximately 273,000 kg CO2e, Scope 2 emissions reaching about 3,793,000 kg CO2e, and Scope 3 emissions significantly higher at around 13,544,000 kg CO2e. This indicates a notable reduction in total emissions from 2023 to 2024. Despite these reductions, Orexo has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company continues to disclose emissions across all three scopes, reflecting a commitment to transparency in its climate impact reporting.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

202220232024
Scope 1
284,000
000,000
000,000
Scope 2
4,053,000
0,000,000
000,000
Scope 3
15,734,000
00,000,000
000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Orexo's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Orexo is in SE, which has a very low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Orexo is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

BioDelivery Sciences International, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 1 minute ago

Merck And Co

US
Pharmaceutical Preparation Manufacturing
Updated less than a minute ago

Headspace, Inc.

US
Health and social work services (85)
Updated 1 minute ago

Indivior

US
Pharmaceutical Preparation Manufacturing
Updated 1 minute ago

Otsuka Pharmaceutical Co., Ltd.

JP
Pharmaceutical Preparation Manufacturing
Updated less than a minute ago

Teva Pharmaceuticals

IL
Pharmaceutical Preparation Manufacturing
Updated 1 minute ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers